Back | Next |
home / stock / cycc / cycc message board
Subject | By | Source | When |
---|---|---|---|
Hyper Oversold --- from $20.xx to $3.23? | Value_Investor | investorshub | 09/18/2020 8:51:34 PM |
$CYCC has bounced to $3.87 so far from | Value_Investor | investorshub | 09/18/2020 8:50:33 PM |
will announce second quarter 2020 financial results on | 02opida | investorshub | 08/11/2020 7:21:32 PM |
3-4 catalyst awaiting this year for this thing, | dinogreeves | investorshub | 08/06/2020 11:52:06 AM |
Riding the waves ! | stock1ace1 | investorshub | 08/06/2020 11:49:52 AM |
News very soon. | dinogreeves | investorshub | 08/01/2020 5:24:45 PM |
News pending thus the move. | dinogreeves | investorshub | 07/31/2020 6:18:08 PM |
Breakout watch | stock1ace1 | investorshub | 07/31/2020 3:49:12 PM |
Should get news soon. | dinogreeves | investorshub | 07/31/2020 3:44:23 PM |
Cyclacel s Clinical Stage CDK2/9 Inhibitor Fadraciclib Targets | 02opida | investorshub | 07/13/2020 12:05:28 PM |
Keep on selling me cheapies | stock1ace1 | investorshub | 07/06/2020 12:52:34 PM |
Ill take em $4.35 thanks | stock1ace1 | investorshub | 07/06/2020 12:52:20 PM |
We got a clown selling @4.50 p/m lol | stock1ace1 | investorshub | 07/06/2020 12:15:04 PM |
Tomorrow it should go chart it :D | stock1ace1 | investorshub | 07/02/2020 7:18:05 PM |
The stage is set waiting on volume | stock1ace1 | investorshub | 07/01/2020 9:09:54 PM |
Got 4.60s filled today ready for a breakout | stock1ace1 | investorshub | 06/29/2020 10:00:25 PM |
8k out on voting matters | stock1ace1 | investorshub | 06/29/2020 9:59:35 PM |
Its about to go SM ;) locked and loaded | stock1ace1 | investorshub | 06/29/2020 3:01:40 PM |
Clearly running now, short term target And Resistance | interloper | investorshub | 05/21/2020 3:40:47 PM |
wow 22 pt | Frankestin | investorshub | 05/19/2020 3:41:36 PM |
News, Short Squeeze, Breakout and More Instantly...
Cyclacel Pharmaceuticals Inc. Company Name:
CYCC Stock Symbol:
NASDAQ Market:
Cyclacel Pharmaceuticals Inc. Website:
BERKELEY HEIGHTS, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the receipt of a notice from the European ...
- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action - BERKELEY HEIGHTS, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”...
- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;...